EXPRESS MAIL NO. EV 207706028US

Please type a plus sign (+) inside this box —> +

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

nder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

are required to respond to a collection of ir	nformation unless it displays a valid OMB control number.		
Application Number	09/485,879		
Filing Date	June 22, 2000		
First Named Inventor	Michael Giesing		
Group Art Unit	1634		
Examiner Name	Jeanine Anne Goldberg		
Attorney Docket No.	790076.401		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Individual Name	Stephen J. Rosenman, Ph.D.	00500 PATENT TRADEMARK OFFICE				
Signature	Shy Cosa-					
Date	March 4, 2003					

D:\NrPortbl\iManage\KARENWILL\361395_1.DOC

EXPRESS MAIL NO. EV 207706028US

PTO/SB/17 (01-03) Approved for use through 04/30/2003. OMB 0651-0032

EE	TR	AN	SMI	ITT	AL
•	for	FY	200	3	

Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27. TOTAL AMOUNT OF PAYMENT 205

Complete If Known				
Application Number	09/485,879			
Filing Date	June 22, 2000			
First Named Inventor	Michael Giesing			
Examiner Name	Jeanine Anne Goldberg	-		
Group Art Unit	1634			
Attorney Docket No.	790076.401			

METHOD OF PAYMENT							
Payment Enclosed: Check Credit card Money Order Other Deposit Account:							
Deposit Account Number							
Deposit Account Name	Seed Int	ellectual	Property Law	Group			
Charge fe	The Commissioner is authorized to (check all that apply) Charge fee(s) indicated below Credit any overpayments Charge any additional fee(s) during the pendency of this application Charge fee(s) indicated below, except for the filing fee Charge any deficiencies to the above-identified deposit account.						
	FEE	CALCULA	TION				
1. BASIC FILING Large Entity S Fee Fee(\$) Code	FEE Small Entity Fee Fee(Code	\$) Fee D	Description	Fee Paid			
1001 750 1002 330 1003 520 1004 750 1005 160	2001 37 2002 16 2003 26 2004 37	Desig Desig Plant Reiss Provis	filing fee n filing fee filing fee ue filing fee sional filing	(\$)			
2. EXTRA CLAIM	EEEe						
Total Claims 84 Independent 5 Multiple Dependent		Extr. Clain = 00		Fee Paid =			
Large Entity	Small Entity	!	L	ا لـــا			
Fee Fee		Fee Fee	Description				
Code (\$) 1202 18		(*)		••			
1202 18 1201 84	2202 2201		ims in excess of				
1201 84	2201		ependent claims				
		** 5	tiple dependent (Reissue indepen	claim, if not paid dent claims over			
1204 84	2204		keissue independ Priginal patent	Jent Claims OVer			
1205 18	2205	9 ** 5	Reissue claims in				
SUBTOTAL (2) (\$) 00							

FEE CALCULATION (continued)						
3. ADDITIONAL FEES						
Large I Fee Code	Fee (\$)	Sm Fee Code	ree (\$)	Fee Description	Fee Paid	
1051	130	2051	65	Surcharge - late filing fee or oath		
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.		
1053	130	1053	130	Non-English specification		
1812	2520	1812	2520	For filing a request for ex parte reexamination		
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action		
1805	1840*	1805	1840°	Requesting publication of SIR after Examiner action		
1251	110	2251	55	Extension for reply within first month		
1252	410	2252	205	Extension for reply within second month	205	
1253	930	2253	465	Extension for reply within third month		
1254	1450	2254	725	Extension for reply within fourth month		
1255	1970	2255	985	Extension for reply within fifth month		
1401	320	2401	160	Notice of Appeal		
1402	320	2402	160	Filing a brief in support of an appeal		
1403	280	2403	140	Request for oral hearing		
1451	1510	1451	1510	Petition to institute a public use proceeding		
1452	110	2452	55	Petition to revive - unavoidable		
1453	1300	2453	650	Petition to revive – unintentional		
1501	1300	2501	650	Utility issue fee (or reissue)	·	
1502	470	2502	235	Design issue fee		
1503	630	2503	315	Plant issue fee		
1460	130	1460	130	Petitions to the Commissioner		
1807	50	1807	50	Processing fee for provisional applications		
1806	180	1806	180	Submission of Information Disclosure Stmt		
8021	40	8021	40	Recording each patent assignment per property (times number of properties)		
1809	750	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))		
1810	750	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))		
1801	750	2801	375	Request for Continued Examination (RCE)		
1802	900	1802	900	Request for expedited examination of a design application		
Other fee	(specify)					

	SUBMITTED BY			
Name (Print/Type)	Stephen J. Rosenman, Ph.D.	Registration Attorney/Ag		
Firm Name/ Address		1		1 (((((((((((((((((((
Signature	Mul. Rosa -	Date N	larch 4, 2003	PATENT

*Reduced by Basic Filing Fee Paid

D:\NrPortbl\iManage\KARENWILL\361394_1.DOC

SUBTOTAL (3)

(\$) 205

TRADEMARK OFFICE



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Michael Giesing et al.

Application No.

09/485,879

Filed

June 22, 2000

For

METHOD FOR THE CHARACTERIZATION OF DISSEMINATED

MICROMETASTASIZED CANCER CELLS

Examiner

Jeanine Anne Goldberg

Art Unit

1634

Docket No.

790076.401

Date

March 4, 2003

Commissioner for Patents Washington, DC 20231

AMENDMENT

Commissioner for Patents:

In response to the Office Action sent October 4, 2002, by the U.S. Patent and Trademark Office (hereinafter PTO), please extend the period for response two months, to expire on March 4, 2003. Enclosed please find a petition for extension of time and the requisite fee. Please amend the application as follows:

In the Claims:

Please amend claims 32, 38-39, 41-43, 45-46, 49, and 52-53 to read as follows:

32. (Twice Amended) The method of either claim 41 or claim 43 wherein at least one nucleic acid selected from the group consisting of (i) a first cancer-associated nucleic acid, (ii) a second cancer-associated nucleic acid, and (iii) a cancer-associated nucleic acid that is present in at least one cancer cell in the second fraction comprises a coding portion of a gene selected from the group consisting of a tissue-specific gene, a metastasis-associated gene, a